Also trades as: 0J2O.L (LSE) · $vol 0M
HALO NASDAQ
Halozyme Therapeutics, Inc.
1W: +3.3%
1M: +13.8%
3M: +54.3%
YTD: +82.8%
1Y: +94.3%
3Y: +265.5%
5Y: +231.5%
$128.50
+0.49 (+0.38%)
After Hours: $128.25 (-0.25, -0.19%)
Weekly Expected Move ±4.8%
$114
$120
$126
$132
$138
Credit Risk of going bust: lower than 70% of companies Debt: 12.9% of company value Bonds: $229.7M held by 80 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.59 (down 99%), Halozyme Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.15B against a stock market value of $14.53B.
Distance to default 7.61 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.18B (short-term plus half of long-term), stock volatility 36.4%; Altman Z'' 3.33. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.59 (down 99%), Halozyme Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.15B against a stock market value of $14.53B.
Distance to default 7.61 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.18B (short-term plus half of long-term), stock volatility 36.4%; Altman Z'' 3.33. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$1.4B
+37.6% ▲
5Y CAGR: +39.2%
Gross Profit
$1.1B
+27.5% ▲
5Y CAGR: +37.2%
Operating Income
$816M
+48.0% ▲
5Y CAGR: +41.4%
Net Income
$317M
-28.6% ▼
5Y CAGR: +19.7%
EPS (Diluted)
$2.56
-25.4% ▼
5Y CAGR: +23.0%
EBITDA
$904M
+37.7% ▲
5Y CAGR: +42.7%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $443M | $660M | $829M | $1.0B | $1.4B |
| YoY Growth | +65.7% | +48.9% | +25.6% | +22.4% | +37.6% |
| Cost of Revenue | $81M | $139M | $192M | $159M | $305M |
| Gross Profit | $362M | $521M | $637M | $856M | $1.1B |
| Gross Margin | 81.6% | 78.9% | 76.8% | 84.3% | 78.1% |
| R&D Expenses | $36M | $67M | $76M | $79M | $81M |
| SG&A Expenses | $50M | $144M | $149M | $154M | $193M |
| Operating Expenses | $86M | $253M | $299M | $304M | $275M |
| Operating Income | $276M | $268M | $338M | $551M | $816M |
| Operating Margin | 62.2% | 40.5% | 40.7% | 54.3% | 58.4% |
| Interest Expense | $8M | $17M | $19M | $18M | $18M |
| Income Before Tax | $249M | $249M | $348M | $557M | $467M |
| Tax Expense | -$154M | $47M | $67M | $113M | $150M |
| Net Income | $403M | $202M | $282M | $444M | $317M |
| Net Margin | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% |
| EPS (Diluted) | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 |
| EBITDA | $259M | $316M | $452M | $657M | $904M |
| Shares Outstanding | 147M | 141M | 134M | 129M | 124M |